Saturday 7 November 2026 Export BRTX’s income statement to Excel — free account

Biorestorative Therapies, Inc.

Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024.

Revenue: −7.20%
EPS: +81.3%
Free cash flow: −35.3%

Quarter to March 2026, against a year earlier

1.48 0.03 −1.99%

Follow BRTX

Alert me

Market cap: $2.1M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 4/9
Altman Z: −69.35
Beneish M: −7.56
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 2.09

Revenue ttm 0.36

Net income ttm (11.06)

Free cash flow ttm (11.82)

Net debt Q (3.59)

Valuation

P/E 0.00

Forward P/E (0.11)

Price / sales 3.67

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.43

Financial health

Current ratio Q 2.35

Debt / equity Q 0.00

Interest coverage Q 615.58

Growth

Revenue growth Q −7.20%

Operating income growth Q +29.57%

EPS, this year +79.11%

EPS, next year A +12.12%

Revenue, next year A −13.82%

EPS, past 5 yrs —

EPS, next 5 yrs A +40.67%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.78%

10-year low 10-year high

P/B against its own 10 years 5.67%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	11	3	4
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	11	11	3	4

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	2	3	1	—
	3	4	4	2

Compound Annual Growth %

	10y	5y	3y
Sales	(5.43%)	36.11%	44.27%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	(71.76%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate −6.00 Actual −3.80

−9.04 −7.22 −5.40 −3.58 −1.76

Q2 FY25 Beat +2.20

Q3 FY25 Met 0.00

Q4 FY25 Met 0.00

Q1 FY26 Beat +2.20

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY25	−8.20	−6.00	Beat by 2.20
Q3 FY25	−7.60	−7.60	Met by 0.00
Q4 FY25	−7.40	−7.40	Met by 0.00
Q1 FY26	−6.00	−3.80	Beat by 2.20
Q3 FY26	−2.60	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.40)	—	—	—	—
’25	(12.80)	(6.00)	(6.60)	(6.40)	(31.60)
’24	(6.60)	(10.00)	(2.60)	(4.00)	(23.20)
’23	(30.60)	(29.38)	7.74	(11.40)	(49.39)
’22	(27.40)	(25.60)	(25.60)	(23.60)	(102.20)
’21	(428.86)	(102.08)	(99.80)	(139.80)	(746.00)
’20	(524.32)	120.22	(41.95)	(125.15)	(571.20)

Fiscal quarters ending in the months shown.

Revenue $m

	Jun	Sep	Dec	Year
’26	—	—	—	—
’25	0	0	0	0
’24	0	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	0
’20	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(2)	(2)	(2)	(2)	(8)
’23	(2)	(1)	(1)	(2)	(6)
’22	(2)	(1)	(1)	(2)	(6)
’21	(1)	(1)	(1)	(1)	(3)
’20	0	0	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(2)	(2)	(2)	(2)	(8)
’23	(2)	(1)	(1)	(2)	(7)
’22	(2)	(1)	(1)	(2)	(6)
’21	(1)	(1)	(1)	(1)	(3)
’20	0	0	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Mar ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	0	0	0	0		+29.0%	0	2	3	+90.8%
	Gross margin, %	99.73	100.00	100.00	100.00	100.00	100.00	100.00	100.00	92.99	93.38	92.09		(6.3) pt	Powerpack Biorestorative Therapies, Inc.’s next three years, line by line Analysts expect revenue to grow 90.8% a year to 2028 — faster than the 29.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(9)	(9)	(13)	(15)	(11)	(44)	(18)	(10)	(9)	(14)	(11)		+5.7%
	EBT margin, %	(23,726.10)	(11,660.12)	(11,277.30)	(11,267.62)	(14,639.87)	(96,311.52)	(15,438.06)	(7,145.20)	(2,239.25)	(3,959.41)	(3,089.30)		+19,766.7 pt
	Net income	(9)	(9)	(13)	(15)	(11)	(44)	(18)	(10)	(9)	(14)	(11)		+5.7%
Per share, $
Per share, $	Revenue	709.28	1,195.04	1,163.77	466.84	3.90	0.77	0.66	0.69	1.03	0.80	0.40		(53.0%)
	Earnings	(168,274.15)	(139,343.08)	(131,246.34)	(52,601.91)	(571.20)	(746.00)	(102.20)	(49.39)	(23.20)	(31.60)	(21.40)		(61.5%)
	Cash flow	(97,480.51)	(56,857.48)	(53,518.56)	(24,845.41)	(99.53)	(56.06)	(32.69)	(30.49)	(21.20)	(23.99)	(13.33)		(60.3%)
	Capex	(3,678.88)	(53.11)	(135.25)	(127.84)	0.00	(0.52)	(2.43)	(0.81)	(0.27)	(0.26)	0.00		(65.4%)
	Free cash flow	(101,159.39)	(56,910.59)	(53,653.81)	(24,973.25)	(99.53)	(56.58)	(35.12)	(31.30)	(21.47)	(24.25)	(13.33)		(60.4%)
	Book value	(97,433.75)	(100,864.56)	(90,595.51)	(45,879.99)	(67.47)	363.59	87.52	47.44	21.98	0.79	3.41		n/m
	Shares, m	0	0	0	0	0	0	0	0	0	0	1		+174.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	37.36	18.27	64.86	0.92	141.23	112.09	82.14	49.76	27.69	29.38	3.67		56.4
	P/B	0.00	0.00	0.00	0.00	0.00	0.24	0.62	0.73	1.30	30.83	0.43		3.4
	EV/Sales	44.67	15.09	68.53	2.12	156.88	(340.86)	(39.38)	(24.83)	1.40	21.70	(5.84)		(9.5)
	EV/FCF	(0.31)	(0.31)	(1.49)	(0.04)	(6.04)	4.62	0.64	0.47	(0.06)	(0.65)	0.16		(0.3)
Cash, $m
Cash, $m	Operating cash flow	(5)	(4)	(5)	(7)	(2)	(3)	(6)	(6)	(8)	(11)	(12)		+8.9%
	Capex	0	0	0	0	—	0	0	0	0	0	0		(5.3%)
	Free cash flow	(5)	(4)	(5)	(7)	(2)	(3)	(6)	(7)	(8)	(11)	(12)		+8.6%
Balance, $m
Balance, $m	Working capital	(6)	(8)	(9)	(14)	2	21	15	9	7	(1)	2		(22.4%)
	Net debt	0	0	0	1	1	(21)	(15)	(11)	(11)	(3)	(4)		n/m
	Shareholders’ equity	(5)	(7)	(9)	(13)	(1)	22	16	10	9	0	3		n/m
Returns, %
Returns, %	ROA	(480.19)	(565.79)	(848.38)	(1,101.88)	(387.82)	(330.62)	(95.12)	(71.73)	(72.15)	(174.11)	(147.75)		+306.1 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	(2,159.78)	(1,095.29)	0.00	0.00	0.00	0.00		0.0 pt
	ROE	193.88	159.58	161.75	136.79	159.81	(437.56)	(98.91)	(80.73)	(97.03)	(321.48)	(241.50)		(515.4) pt
People
People	Employees	11	9	9	6	5	7	10	11	11	14	—		+2.7%
	Revenue/emp, $m	0.00	0.01	0.01	0.02	0.02	0.01	0.01	0.01	0.04	0.03	—		+25.6%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HCWB HCW Biologics Inc.	$2.3M	— (loss-making)	— (loss-making)	+1,954.55% (above 0%: growing)	n/m	−20.84% (below 0%: shrinking)	(69.25%)	(2,335.03%)	Compare
APVO Aptevo Therapeutics Inc.	$2.3M	— (loss-making)	— (loss-making)	+28.62% (above 0%: growing)	n/m	+23.11% (above 0%: growing)	0.00%	0.00%	Compare
SLXN Silexion Therapeutics Corp	$2.2M	— (loss-making)	—	—	n/m	−16.63% (below 0%: shrinking)	—	0.00%	Compare
BRTX Biorestorative Therapies, Inc.	$2.1M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)
SILO Silo Pharma, Inc.	$2.1M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%	Compare
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%	Compare
REVB Revelation Biosciences, Inc.	$2.0M	— (loss-making)	—	—	n/m	−35.29% (below 0%: shrinking)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$2.0M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
EDVA Splash Beverage Group, Inc.	$1.9M	— (loss-making)	— (loss-making)	−99.57% (below 0%: shrinking)	n/m	−95.72% (below 0%: shrinking)	42.86%	0.00%	Compare
Median of peers	$2.0M	—	—	+14.31%	—	−18.74%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 13 April 2026

Ownership

Directors and executive officers, together 13.60%

Louis Posner 9.99%

Alta Partners LLC 7.00%

Lance Alstodt 5.70%

Francisco Silva 5.50%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Biorestorative Therapies, Inc. (BRTX) Latest News

25 Jun

Impact 4 · 8:15 AM · GlobeNewswire

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

18 Jun

Impact 3 · 8:15 AM

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

26 May

Impact 3 · 11:00 AM · GlobeNewswire

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

15 May

Impact 3 · 12:00 PM · Zacks

What Makes Biorestorative Therapies (BRTX) a New Buy Stock

14 May

Impact 3 · 7:40 PM · Zacks

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates

13 May

Impact 3 · 11:00 AM · GlobeNewswire

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

7 May

Impact 4 · 12:00 PM · GlobeNewswire

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

30 Apr

Impact 3 · 10:36 AM · GlobeNewswire

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

21 Apr

Impact 4 · 8:00 AM

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

7 Apr

Impact 4 · 8:15 AM · GlobeNewswire

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

30 Mar

Impact 4 · 8:00 AM · GlobeNewswire

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

26 Mar

Impact 3 · 6:25 PM · Zacks

Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates

19 Mar

Impact 4 · 8:00 AM · GlobeNewswire

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

4 Mar

Impact 4 · 8:00 AM · GlobeNewswire

BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

24 Feb

Impact 4 · 8:30 AM · GlobeNewswire

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

13 Feb

Impact 3 · 8:30 PM

BioRestorative Announces Closing of $5.0 Million Public Offering

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

11 Feb

Impact 4 · 7:30 AM · GlobeNewswire

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

Impact 3 · 10:30 PM · GlobeNewswire

BioRestorative Announces Pricing of $5.0 Million Public Offering

10 Feb

Impact 4 · 8:00 AM · GlobeNewswire

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

17 Nov

Impact 4 · 7:00 AM · GlobeNewswireMotley FoolGuruFocus.comMT NewswiresMT NewswiresGuruFocus.comExec EdgeMT Newswires

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

13 Nov

Impact 4 · 12:04 PM · The Motley Fool transcript

BioRestorative (BRTX) Earnings Call Transcript

Impact 4 · 12:01 AM · GuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com transcript

BioRestorative Therapies Inc (BRTX) Q3 2025 Earnings Call Highlights: Strategic Advancements ...

12 Nov

Impact 3 · 6:25 PM · Zacks

Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates

Impact 3 · 4:05 PM · GlobeNewswire

BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

27 Oct

Impact 4 · 7:30 AM · GlobeNewswire

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

22 Oct

Impact 4 · 9:35 AM · GlobeNewswire

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

15 Oct

Impact 3 · 9:35 AM · GlobeNewswireInsider MonkeyMT NewswiresMT NewswiresInsider MonkeyMT NewswiresMT NewswiresMT Newswires

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

7 Oct

Impact 3 · 9:25 AM · GlobeNewswire

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

6 Oct

Impact 3 · 2:28 PM · GlobeNewswire

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Biorestorative Therapies, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 13 April 2026

Ownership

Biorestorative Therapies, Inc. (BRTX) Latest News

25 Jun

18 Jun

26 May

15 May

14 May

13 May

7 May

30 Apr

21 Apr

7 Apr

30 Mar

26 Mar

19 Mar

4 Mar

24 Feb

13 Feb

11 Feb

10 Feb

17 Nov

13 Nov

12 Nov

27 Oct

22 Oct

15 Oct

7 Oct

6 Oct

Stockrow Weekly